

Medical treatments for incurable diseases, palliative therapy

Abstract

Chronic and aggressive diseases are commonly incurable. Palliative and nursery care are newly practiced that aims to disease managements outside normal therapy. Better medical service and symptom alleviations of incurable congenital diseases can satisfy patients with reduce therapeutic costs and a long period of times. In this article, relevant medical disciplines and drug developments are provided—from technique detail to medical knowledge as well as clinical applications in a broader-range.

Keywords: healthcare, nursing, service promotion, herbal medicine, palliative treatment, psycho-analysis

Volume 3 Issue 5 - 2019

Da-Yong Lu,¹ Hong Yig Wu,¹ Ying Shen,² Bin Xu,³ Ting-Ren Lu¹

¹Shanghai University, China

²Shanghai Jiao-Tong University, China

³Shanghai Institute of Materia Medica, China

Correspondence: Da Yong Lu, School of Life Sciences, Shanghai University, Shanghai200444, PRC, China, Email luyayng@shu.edu.cn

Received: November 21, 2019 | **Published:** December 17, 2019

Introduction

Chronic and aggressive diseases are commonly incurable. Palliative and nursery care are widest practiced that aims to disease managements outside normal therapy. Better medical service of these incurable diseases can satisfy patients with a reduce therapeutic cost. In this article, relevant medical disciplines and drug developments are provided—from technique detail to medical knowledge as well as clinical applications in a broader-range. Palliative care and nursing advances help patient's recovery and disease controls in the clinic. The medical significance of the quality improvements of medical healthcare and nursing activity is notable.

Methods

Major disease for palliative Treatments,¹:

- Congenital diseases
- Cancer-related diseases
- Neuromuscular diseases
- Respiratory diseases
- Gastrointestinal diseases
- And others

Results

The incurable diseases suitable for palliative therapies are characterized with deadly symptoms, such as neoplasm metastasis, cystic fibrosis and others. The diseases are aggressively progressed in patients because there is no therapeutics against disease pathogen (neoplasm metastasis or increasing mucosa secretes in human bronchus channels). Correspondingly, proper managements against deadly symptoms are welcomed by patients. Palliative therapeutics usually alleviates patient's pain, psychiatric states and overall conditions.

- Nutritional fortification
- Herbal medicine

- High quality of nursing
- Symptom alleviation (pain or lean)
- Psychiatric control
- Assistant therapy
- Therapeutic or drug combination
- Disease maintaining.²⁻¹³

Discussion

One of these palliative strategies is herbal medicine. Herbal medicine seldom targets disease pathogens while regulate the human function of immunity, neuropsychiatry and endocrinology,¹⁴⁻¹⁷ This therapeutic modality may be very useful as palliative therapy. Drug combination is the commonly way of refractory diseases treatments.¹⁸⁻²¹ They can act both pathogens and symptoms. This way of therapeutic option can be improved greatly in the future. Palliative medicine is very useful in the clinical trials. They are commonly less harmful for patients. But most of palliative treatments need to long-term utility because the disease origins and pathogens are not removed by these treatments. They are commonly not expensive. They assist to main-stream therapy. In summary, doctors and nurses should be familiar with all these knowledge of medical disciplines and execute their service in high quality and satisfy more patients.

Conclusion

Palliative treatment plays key roles for deadly patients. After all, doctors and nursery training should be more emphasized for this medical discipline. Commonly, a great difference can be made by therapeutic promotion and creativity. There is a long way to move forwards and fill the gap between therapeutic convention and palliative treatments.

Funding

None.

Acknowledgments

None.

Conflicts of interest

The authors declare no conflict of interest.

References

- Prityko DA, Burkov IV, Safonov VV, et al. Palliative care for children, problems and ways to solve them. *EC Clinical & Experimental anatomy*. 2019;2(9):23–29.
- While D, Bickley H, Roscoe A, et al. Implementation of mental health service recommendations in England and Wales and suicide rates, 1997–2006: a cross-sectional and before-and-after observational study. *Lancet*. 2012;379:1005–1012.
- Lu DY, Lu TR, Wu HY, et al. Cancer Metastasis treatments. *Current Drug Therapy*. 2013;8(1):24–29.
- Lu DY, Xu B, Ding J. Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo. *BMC Pharmacol*. 2004;4:32.
- Lu DY, Chen XL, Ding J. Treatment of solid tumors and metastases by fibrinogen-targeted anticancer drug therapy. *Medical Hypotheses*. 2007;68(1):188–193.
- Lu DY, Lu TR. Antimetastatic activities and mechanisms of bisdioxopiperazine compounds. *Anti-Cancer Agents Med Chem*. 2010;10(7):564–570.
- Lambert, AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. *Cell*. 2017;168(4):670–691.
- Lu DY, Chen YZ, Lu DF, et al. Patient's care and nursery in different diseases. *Hos Pal Med Int Jnl*. 2019;3(1): 28–30.
- Lu DY, Chen YZ, Lu DF, et al. Patient's care and nursery in modern medicine. *Nursing Practice and Health Care*. 2019;1(1):1–2.
- Lu DY, Chen YZ, Lu DF. Nursery education, capability and service promotion. *Open Access J Nursery*. 2019;2(2);1–4.
- Leebov W, Scott G. Service quality improvement. The customer satisfaction strategy for healthcare. *The Journal of Continuing Education in Nursing*. 1995;26(1):46.
- Lu DY, Chen YZ, Lu DF. Nursery service, quality promotion. *Hos Pal Med Int Jnl*. 2019;3(3):97–98.
- Lu DY, Chen YZ, Lu DF, et al. Nursery service in modern day. *Adv Biomedical Engineering Biotechnology*. 2019;1(3):1–2.
- Lu DY, Lu TR. Herbal medicine in new era. *Hos Pal Med Int Jnl*. 2019;3(4):125–130.
- Yang G, Li X, Li X, et al. Traditional Chinese medicine in cancer care: a review of controlled clinical studies published in chinese. *PLoS One*. 2013;8(4):e60338.
- Lu DY, Lu TR, Putta S, et al. Anticancer drug discoveries from herbal medicine. *EC Pharmacology Toxicology*. 2019;7(9):990–994.
- Parasuraman S. Herbal drug discovery: challenges and perspectives. *Current Pharmacogenetics Personalized Medicine*. 2018;16(1):63–68.
- Lu DY, Chen EH, Wu HY, et al. Anticancer drug combination, how far we can go through?. *Anticancer Agents Med Chem*. 2017;17(1):21–28.
- Lu DY, Lu TR, Yarla NS, et al. Drug combination in clinical cancer treatment. *Rev Recent Clin Trials*. 2017;12(3):202–211.
- Lu DY, Lu TR, Chen XL, et al. Plasma fibrinogen concentrations in patients with solid tumor and therapeutic improvements by combining anticoagulants and fibrinolytical agents. *Adv Pharmacoepidemiol Drug Saf*. 2015;4(4):e133.
- Lu DY, Lu TR, Chen EH, et al. Tumor fibrin/fibrinogen matrix as a unique therapeutic target for pulmonary cancer growth and metastases. *Clin Res Pulmonol*. 2015;3(1):1027.